Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2019

June 2019 | 63 pages | ID: C5D1946E83BEN
Global Markets Direct

Abstracts

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2019

SUMMARY

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e is a human gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. It promotes tumor development through its role as a cell adhesion molecule. It regulates differentiation, apoptosis, and cell polarity.

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 2 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Adenocarcinoma, Bladder Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pancreatic Cancer, Peritoneal Tumor, Recurrent Glioblastoma Multiforme (GBM) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)
• The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects
• The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Overview
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Companies Involved in Therapeutics Development
Akshaya Bio Inc
Bavarian Nordic A/S
Etubics Corp
OSE Immunotherapeutics
Vaxon Biotech
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drug Profiles
CV-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GI-6207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Virus to Target CD66e for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSE-2101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CEA for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CEA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Dormant Products
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Discontinued Products
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Product Development Milestones
Featured News & Press Releases
May 22, 2019: OSE Immunotherapeutics to host key opinion leader meeting on novel treatments in non-small cell lung cancer
Apr 02, 2019: OSE Immunotherapeutics Presented new clinical data on Tedopi (OSE2101) at AACR 2019
Feb 28, 2019: OSE Immunotherapeutics to present new clinical data on its immuno-oncology portfolio Tedopi at AACR 2019
Jan 15, 2019: OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi to treat brain metastasis
Nov 21, 2018: OSE receives approval for Phase II trial of tedopi and opdivo
Nov 02, 2018: Bavarian Nordic announces initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers
Oct 10, 2018: Ose Immunotherapeutics and oncology physician network Gercor announce submission of investigational new drug application to evaluate Tedopi in combination with Nivolumab in pancreatic cancer
Sep 20, 2018: Bavarian doses first patient in CV301 and atezolizumab Phase ll trial
Aug 10, 2018: HCRN study explores investigational vaccine therapy for metastatic colorectal cancer
Jul 11, 2018: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
Jul 05, 2018: OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi
Jul 02, 2018: OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi
Jun 19, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer
Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
Mar 08, 2018: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Akshaya Bio Inc, H1 2019
Pipeline by Bavarian Nordic A/S, H1 2019
Pipeline by Etubics Corp, H1 2019
Pipeline by OSE Immunotherapeutics, H1 2019
Pipeline by Vaxon Biotech, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Discontinued Products, H1 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

COMPANIES MENTIONED

Akshaya Bio Inc
Bavarian Nordic A/S
Etubics Corp
OSE Immunotherapeutics
Vaxon Biotech